首页 > 最新文献

Clinical Pediatric Endocrinology最新文献

英文 中文
High-dose fludrocortisone therapy was transiently required in a female neonate with 21-hydroxylase deficiency 高剂量氢化可的松治疗是暂时需要的女性新生儿21羟化酶缺乏症
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-03-05 DOI: 10.1297/cpe.2021-0066
Y. Kawasaki, Takeshi Sato, Satsuki Nakano, T. Usui, S. Narumi, T. Ishii, T. Hasegawa
Abstract. For salt-wasting 21-hydroxylase deficiency (21OHD), fludrocortisone (FC) is usually supplemented at 0.05–0.2 mg/d dose. To date, no report has described 21OHD neonates requiring > 0.4 mg/d of FC. Our female 21OHD patient was lethargic and experienced weight loss with hyponatremia (133 mEq/L), hyperkalemia (6.5 mEq/L), and elevated active renin concentration (ARC, 1942.2 pg/mL) at 6 days of life. Hydrocortisone and FC replacement were initiated. FC dose was gradually increased to 0.4 mg/d at 21 days of life, but her hyperkalemia (6.4 mEq/L) and high ARC (372.3 pg/mL) persisted. We increased FC to 0.6 mg/d and used a low-potassium and high-sodium formula. Hyperkalemia subsequently improved. At 33 days of life, the ARC decreased to 0.6 pg/mL and FC dosage was gradually decreased. At 3 months of age, the low-potassium and high-sodium formula was discontinued, but the serum potassium level was normal and ARC remained low at 0.1 mg/d of FC. We speculated that severe mineralocorticoid resistance was the reason why her hyperkalemia persisted even with 0.4 mg/d of FC; however, the pathophysiology of transiently severe resistance to FC in this patient is unknown. In conclusion, 21OHD neonates may show severe salt-wasting that transiently require > 0.4 mg/d of FC.
摘要对于盐耗性21-羟化酶缺乏症(21OHD),通常以0.05-0.2 mg/d的剂量补充氟化可的松(FC)。到目前为止,还没有报道称21OHD新生儿需要每天摄入0.4毫克的FC。我们的女性21OHD患者在出生第6天出现嗜睡和体重下降,并伴有低钠血症(133 mEq/L)、高钾血症(6.5 mEq/L)和活性肾素浓度升高(ARC, 1942.2 pg/mL)。开始使用氢化可的松和FC替代。21天时,FC剂量逐渐增加至0.4 mg/d,但高钾血症(6.4 mEq/L)和高ARC (372.3 pg/mL)持续存在。我们将FC增加到0.6 mg/d,并使用低钾高钠配方。高钾血症随后得到改善。33 d时,ARC降至0.6 pg/mL, FC用量逐渐减少。3月龄时停用低钾高钠配方,但血清钾水平正常,ARC维持在0.1 mg/d FC的低水平。我们推测严重的矿物皮质激素抵抗是她即使在0.4 mg/d的FC下仍持续高钾血症的原因;然而,该患者对氟氯化碳短暂性严重耐药的病理生理机制尚不清楚。综上所述,21OHD新生儿可能表现出严重的盐耗,暂时需要0.4 mg/d的FC。
{"title":"High-dose fludrocortisone therapy was transiently required in a female neonate with 21-hydroxylase deficiency","authors":"Y. Kawasaki, Takeshi Sato, Satsuki Nakano, T. Usui, S. Narumi, T. Ishii, T. Hasegawa","doi":"10.1297/cpe.2021-0066","DOIUrl":"https://doi.org/10.1297/cpe.2021-0066","url":null,"abstract":"Abstract. For salt-wasting 21-hydroxylase deficiency (21OHD), fludrocortisone (FC) is usually supplemented at 0.05–0.2 mg/d dose. To date, no report has described 21OHD neonates requiring > 0.4 mg/d of FC. Our female 21OHD patient was lethargic and experienced weight loss with hyponatremia (133 mEq/L), hyperkalemia (6.5 mEq/L), and elevated active renin concentration (ARC, 1942.2 pg/mL) at 6 days of life. Hydrocortisone and FC replacement were initiated. FC dose was gradually increased to 0.4 mg/d at 21 days of life, but her hyperkalemia (6.4 mEq/L) and high ARC (372.3 pg/mL) persisted. We increased FC to 0.6 mg/d and used a low-potassium and high-sodium formula. Hyperkalemia subsequently improved. At 33 days of life, the ARC decreased to 0.6 pg/mL and FC dosage was gradually decreased. At 3 months of age, the low-potassium and high-sodium formula was discontinued, but the serum potassium level was normal and ARC remained low at 0.1 mg/d of FC. We speculated that severe mineralocorticoid resistance was the reason why her hyperkalemia persisted even with 0.4 mg/d of FC; however, the pathophysiology of transiently severe resistance to FC in this patient is unknown. In conclusion, 21OHD neonates may show severe salt-wasting that transiently require > 0.4 mg/d of FC.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 1","pages":"93 - 97"},"PeriodicalIF":1.4,"publicationDate":"2022-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48869186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Oral disintegrating desmopressin tablet is effective for partial congenital nephrogenic diabetes insipidus with AVPR2 mutation: a case report 口服去氨加压素崩解片治疗AVPR2突变部分先天性肾源性尿崩症1例疗效观察
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-02-18 DOI: 10.1297/cpe.2021-0032
K. Ikegawa, R. Hachiya, K. Akiba, Y. Hasegawa
Abstract. Congenital nephrogenic diabetes insipidus (NDI) is a rare disease that causes polydipsia and polyuria, and there are currently no effective treatments for most cases, particularly severe ones. The present report describes the case of a 1-yr-5-mo-old male patient with partial congenital NDI who was successfully treated with oral disintegrating 1-deamino-8-D-arginine vasopressin (DDAVP). The patient presented with poor weight gain and polydipsia (fluid, 1.5 L/d) and received a diagnosis of NDI after genetic analysis revealed an AVPR2 mutation (c.383A>C, p.Y128S). His water-restricted urine osmolality increased from 360 mOsm/kg/H2O to 667 mOsm/kg/H2O after subcutaneous AVP injection, indicating that he had some urine concentrating ability. Oral disintegrating DDAVP therapy was started at 360 µg/d with hydrochlorothiazide and increased to 720 µg/d without any adverse effects. A 30% decrease in urine output and water intake was followed by an increase in body weight. The present study is the first to report the effectiveness and safety of oral disintegrating DDAVP in a patient with partial congenital NDI due to an AVPR2 gene mutation. The severity of NDI at which DDAVP therapy is the most effective remains to be determined.
摘要先天性肾源性尿崩症(NDI)是一种罕见的导致多饮和多尿的疾病,目前对大多数病例,特别是严重病例,没有有效的治疗方法。本报告描述了一例1至5岁患有部分先天性NDI的男性患者,该患者成功地接受了口腔崩解1-二氨基-8-D-精氨酸加压素(DDAVP)治疗。患者表现为体重增加不良和多饮(液体,1.5 L/d),在基因分析显示AVPR2突变(c.383A>c,p.Y128S)后,患者被诊断为NDI。皮下注射AVP后,其水限制性尿液渗透压从360 mOsm/kg/H2O增加到667 mOsm/kg/H2O,表明其具有一定的尿液浓缩能力。口腔崩解DDAVP治疗从360µg/d开始使用氢氯噻嗪,并增加到720µg/d,没有任何不良反应。尿量和水摄入量减少30%后,体重增加。本研究首次报道了口腔崩解DDAVP治疗因AVPR2基因突变导致的部分先天性NDI患者的有效性和安全性。DDAVP治疗最有效的NDI的严重程度仍有待确定。
{"title":"Oral disintegrating desmopressin tablet is effective for partial congenital nephrogenic diabetes insipidus with AVPR2 mutation: a case report","authors":"K. Ikegawa, R. Hachiya, K. Akiba, Y. Hasegawa","doi":"10.1297/cpe.2021-0032","DOIUrl":"https://doi.org/10.1297/cpe.2021-0032","url":null,"abstract":"Abstract. Congenital nephrogenic diabetes insipidus (NDI) is a rare disease that causes polydipsia and polyuria, and there are currently no effective treatments for most cases, particularly severe ones. The present report describes the case of a 1-yr-5-mo-old male patient with partial congenital NDI who was successfully treated with oral disintegrating 1-deamino-8-D-arginine vasopressin (DDAVP). The patient presented with poor weight gain and polydipsia (fluid, 1.5 L/d) and received a diagnosis of NDI after genetic analysis revealed an AVPR2 mutation (c.383A>C, p.Y128S). His water-restricted urine osmolality increased from 360 mOsm/kg/H2O to 667 mOsm/kg/H2O after subcutaneous AVP injection, indicating that he had some urine concentrating ability. Oral disintegrating DDAVP therapy was started at 360 µg/d with hydrochlorothiazide and increased to 720 µg/d without any adverse effects. A 30% decrease in urine output and water intake was followed by an increase in body weight. The present study is the first to report the effectiveness and safety of oral disintegrating DDAVP in a patient with partial congenital NDI due to an AVPR2 gene mutation. The severity of NDI at which DDAVP therapy is the most effective remains to be determined.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 1","pages":"87 - 92"},"PeriodicalIF":1.4,"publicationDate":"2022-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48807134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe hypernatremia in soft drink ketoacidosis and hyperglycemic hyperosmolar state at the onset of type 2 diabetes mellitus: a case series of three adolescents 2型糖尿病发病时伴有软饮料酮症酸中毒和高血糖高渗状态的严重高钠血症:3例青少年病例系列
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-02-16 DOI: 10.1297/cpe.2021-0075
Soo Jeong Choo, Hyun Gyung Lee, C. Kim, E. Yang
Abstract. Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are diabetic emergencies. Some patients with a hyperglycemic crisis can present with an overlap of DKA and HHS. The coexistence of DKA and HHS is associated with higher mortality than in isolated DKA and HHS. In addition, electrolyte derangements caused by global electrolyte imbalance are associated with potentially life-threatening complications. Here, we describe three cases of mixed DKA and HHS with severe hypernatremia at the onset of type 2 diabetes mellitus. All patients had extreme hyperglycemia and hyperosmolarity with acidosis at the onset of diabetes mellitus. They consumed 2 to 3 L/d of high-carbohydrate drinks prior to admission to relieve thirst. They showed severe hypernatremia with renal impairment. Two patients recovered completely without any complications, while one died. Severe hypernatremia with mixed DKA and HHS is rare. However, it may be associated with excess carbohydrate beverage consumption. Reduced physical activity during the COVID19 pandemic and unhealthy eating behaviors worsened the initial presentation of diabetes mellitus. We highlight the impact of lifestyle factors on mixed DKA and HHS.
摘要糖尿病酮症酸中毒(DKA)和高血糖高渗状态(HHS)是糖尿病的紧急情况。一些患有高血糖危机的患者可能会出现DKA和HHS的重叠。与单独的DKA和HHS相比,DKA和HHS的共存与更高的死亡率相关。此外,全球电解质失衡引起的电解质紊乱与潜在的危及生命的并发症有关。在这里,我们描述了三例2型糖尿病发病时伴有严重高钠血症的DKA和HHS混合病例。所有患者在糖尿病发作时都有极度高血糖和高渗伴酸中毒。他们在入院前每天饮用2至3升的高碳水化合物饮料以解渴。他们表现出严重的高钠血症伴肾功能损害。两名患者完全康复,没有任何并发症,一名患者死亡。混合DKA和HHS的严重高钠血症是罕见的。然而,它可能与过量的碳水化合物饮料消费有关。新冠肺炎疫情期间减少的体力活动和不健康的饮食行为恶化了糖尿病的最初表现。我们强调了生活方式因素对DKA和HHS混合的影响。
{"title":"Severe hypernatremia in soft drink ketoacidosis and hyperglycemic hyperosmolar state at the onset of type 2 diabetes mellitus: a case series of three adolescents","authors":"Soo Jeong Choo, Hyun Gyung Lee, C. Kim, E. Yang","doi":"10.1297/cpe.2021-0075","DOIUrl":"https://doi.org/10.1297/cpe.2021-0075","url":null,"abstract":"Abstract. Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are diabetic emergencies. Some patients with a hyperglycemic crisis can present with an overlap of DKA and HHS. The coexistence of DKA and HHS is associated with higher mortality than in isolated DKA and HHS. In addition, electrolyte derangements caused by global electrolyte imbalance are associated with potentially life-threatening complications. Here, we describe three cases of mixed DKA and HHS with severe hypernatremia at the onset of type 2 diabetes mellitus. All patients had extreme hyperglycemia and hyperosmolarity with acidosis at the onset of diabetes mellitus. They consumed 2 to 3 L/d of high-carbohydrate drinks prior to admission to relieve thirst. They showed severe hypernatremia with renal impairment. Two patients recovered completely without any complications, while one died. Severe hypernatremia with mixed DKA and HHS is rare. However, it may be associated with excess carbohydrate beverage consumption. Reduced physical activity during the COVID19 pandemic and unhealthy eating behaviors worsened the initial presentation of diabetes mellitus. We highlight the impact of lifestyle factors on mixed DKA and HHS.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 1","pages":"81 - 86"},"PeriodicalIF":1.4,"publicationDate":"2022-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49191620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Various phenotypes of short stature with heterozygous IGF-1 receptor (IGF1R) mutations IGF-1受体(IGF1R)杂合突变导致的各种矮小表型
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-02-07 DOI: 10.1297/cpe.2021-0064
Yuki Kawashima-Sonoyama, T. Hotsubo, T. Hamajima, N. Hamajima, M. Fujimoto, N. Namba, S. Kanzaki
Abstract. Type 1 insulin-like growth factor receptor (IGF1R) plays an important role in normal fetal and postnatal growth. Over 30 pathogenic variants of IGF1R have been identified in patients with short stature. Yet, 20 years after the first report, a variety of phenotypes remain poorly defined. We analyzed the genetic and clinical data and responses to GH therapy in 11 patients using results from questionnaires. Eight of the 11 patients have already been reported in previous articles, and all of the identified mutations were heterozygous. The patients exhibited various phenotypes. At least two patients did not meet the criteria for GH treatment for small for gestational age (SGA) short stature, and two more patients showed lower serum IGF1 levels. Nine of the 11 patients had thin upper lips. Five patients with heterozygous IGF1R treated with GH exhibited similar height gains to those reported in previous Japanese studies on SGA short stature, which also led to extremely high serum IGF1 levels. Patients with short stature due to IGF1R mutations exhibit various phenotypes. Their presentation at diagnosis may be indistinguishable from common short stature. More specific clinical scoring that considers elevated IGF1 levels after GH treatment is needed to better detect IGF1R mutations.
摘要1型胰岛素样生长因子受体(IGF1R)在胎儿和产后的正常生长中起着重要作用。在身材矮小的患者中已经发现了30多种IGF1R的致病性变体。然而,在第一份报告发布20年后,各种表型仍然定义不清。我们使用问卷调查结果分析了11名患者的遗传和临床数据以及对GH治疗的反应。在之前的文章中已经报道了11名患者中的8名,并且所有确定的突变都是杂合的。患者表现出不同的表型。至少有两名患者不符合妊娠期小(SGA)身材矮小的GH治疗标准,另有两名患者血清IGF1水平较低。11名患者中有9名上唇较薄。五名接受GH治疗的杂合IGF1R患者的身高增加与日本先前关于SGA身材矮小的研究中报道的相似,这也导致了极高的血清IGF1水平。IGF1R突变导致身材矮小的患者表现出各种表型。他们在诊断时的表现可能与常见的矮小无法区分。需要考虑GH治疗后IGF1水平升高的更具体的临床评分来更好地检测IGF1R突变。
{"title":"Various phenotypes of short stature with heterozygous IGF-1 receptor (IGF1R) mutations","authors":"Yuki Kawashima-Sonoyama, T. Hotsubo, T. Hamajima, N. Hamajima, M. Fujimoto, N. Namba, S. Kanzaki","doi":"10.1297/cpe.2021-0064","DOIUrl":"https://doi.org/10.1297/cpe.2021-0064","url":null,"abstract":"Abstract. Type 1 insulin-like growth factor receptor (IGF1R) plays an important role in normal fetal and postnatal growth. Over 30 pathogenic variants of IGF1R have been identified in patients with short stature. Yet, 20 years after the first report, a variety of phenotypes remain poorly defined. We analyzed the genetic and clinical data and responses to GH therapy in 11 patients using results from questionnaires. Eight of the 11 patients have already been reported in previous articles, and all of the identified mutations were heterozygous. The patients exhibited various phenotypes. At least two patients did not meet the criteria for GH treatment for small for gestational age (SGA) short stature, and two more patients showed lower serum IGF1 levels. Nine of the 11 patients had thin upper lips. Five patients with heterozygous IGF1R treated with GH exhibited similar height gains to those reported in previous Japanese studies on SGA short stature, which also led to extremely high serum IGF1 levels. Patients with short stature due to IGF1R mutations exhibit various phenotypes. Their presentation at diagnosis may be indistinguishable from common short stature. More specific clinical scoring that considers elevated IGF1 levels after GH treatment is needed to better detect IGF1R mutations.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 1","pages":"59 - 67"},"PeriodicalIF":1.4,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41732566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel nonsense variant (p.Arg1293Ter) of the immunoglobulin superfamily 1 (IGSF1) associated with congenital hypogonadotropic hypogonadism and central hypothyroidism 免疫球蛋白超家族1(IGSF1)的一种新的无义变体(p.Arg1293Ter)与先天性促性腺功能减退症和中枢性甲状腺功能减退症有关
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-14 DOI: 10.1297/cpe.2021-0071
T. Tajima, Makiko Oguma
Individuals with deletions and/or pathogenic variants of the Immunoglobulin superfamily 1 (IGSF1) gene may show congenital central hypothyroidism (CCH) (1–3). In addition, these individuals may have PRL deficiency and, in a small number of cases, GH deficiency. Furthermore, the onset of puberty tends to be delayed, and is often accompanied by giant testes. Despite the early replacement of thyroid hormone, CCH may be accompanied by developmental disorders and attention deficit hyperactivity syndrome (2, 3). However, asymptomatic cases have also been reported. We report the identification of a novel nonsense variant (p.Arg1293Ter) of IGSF1 in a young male patient with congenital hypogonadotropic hypogonadism (CHH), CCH, and GH deficiency.
免疫球蛋白超家族1 (IGSF1)基因缺失和/或致病性变异的个体可能表现为先天性中枢性甲状腺功能减退症(CCH)(1 - 3)。此外,这些人可能有PRL缺乏症,在少数情况下,生长激素缺乏症。此外,青春期的开始往往被推迟,并经常伴随着巨大的睾丸。尽管早期更换甲状腺激素,但CCH可能伴有发育障碍和注意缺陷多动综合征(2,3)。然而,也有无症状病例的报道。我们在一例患有先天性促性腺功能低下(CHH)、CCH和GH缺乏症的年轻男性患者中发现了一种新的无义IGSF1变异(p.a g1293ter)。
{"title":"A novel nonsense variant (p.Arg1293Ter) of the immunoglobulin superfamily 1 (IGSF1) associated with congenital hypogonadotropic hypogonadism and central hypothyroidism","authors":"T. Tajima, Makiko Oguma","doi":"10.1297/cpe.2021-0071","DOIUrl":"https://doi.org/10.1297/cpe.2021-0071","url":null,"abstract":"Individuals with deletions and/or pathogenic variants of the Immunoglobulin superfamily 1 (IGSF1) gene may show congenital central hypothyroidism (CCH) (1–3). In addition, these individuals may have PRL deficiency and, in a small number of cases, GH deficiency. Furthermore, the onset of puberty tends to be delayed, and is often accompanied by giant testes. Despite the early replacement of thyroid hormone, CCH may be accompanied by developmental disorders and attention deficit hyperactivity syndrome (2, 3). However, asymptomatic cases have also been reported. We report the identification of a novel nonsense variant (p.Arg1293Ter) of IGSF1 in a young male patient with congenital hypogonadotropic hypogonadism (CHH), CCH, and GH deficiency.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 1","pages":"98 - 100"},"PeriodicalIF":1.4,"publicationDate":"2022-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43293885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Does COVID-19 predispose patients to type 1 diabetes mellitus? COVID-19是否使患者易患1型糖尿病?
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-01 Epub Date: 2021-11-01 DOI: 10.1297/cpe.2021-0050
Aysun Ata, Arzu Jalilova, Tarık Kırkgöz, Hafize Işıklar, Günay Demir, Yasemin Atik Altınok, Behzat Özkan, Ayşin Zeytinlioğlu, Şükran Darcan, Samim Özen, Damla Gökşen

The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo-18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.

新型冠状病毒病(COVID-19)已成为全球大流行。这是一项在土耳其伊兹密尔进行的前瞻性病例对照研究。本研究的目的是评估COVID-19与新发T1DM之间的关系。我们纳入了2020年4月至2021年1月期间在COVID-19大流行期间诊断为新发1型糖尿病(T1DM)的儿科患者(6岁至18岁)。入院后采用聚合酶链反应诊断COVID-19。确诊后进行针对SARS-CoV-2的IgM和IgG酶联免疫测定。对照组尽可能在T1DM患者转诊时进行血抗体检测。该研究共纳入118名参与者,包括57名(48%)新发T1DM患者和61名(52%)健康对照。57例患者中,36例(63.2%)为DKA, 17例(29.7%)为糖尿病酮症,4例(7%)为偶发。5名T1DM患者(8.7%)和6名对照患者(10%)的SARS-CoV-2抗体检测呈阳性。两组间的阳性率差异无统计学意义(p = 0.901)。不可能证明SARS-CoV-2感染与新发T1DM之间存在明确关联。SARS-CoV-2是否通过触发胰岛细胞自身免疫而增加对糖尿病的易感性,并影响已有自身免疫的患者出现显性糖尿病的时间,应在大队列中进行研究。
{"title":"Does COVID-19 predispose patients to type 1 diabetes mellitus?","authors":"Aysun Ata,&nbsp;Arzu Jalilova,&nbsp;Tarık Kırkgöz,&nbsp;Hafize Işıklar,&nbsp;Günay Demir,&nbsp;Yasemin Atik Altınok,&nbsp;Behzat Özkan,&nbsp;Ayşin Zeytinlioğlu,&nbsp;Şükran Darcan,&nbsp;Samim Özen,&nbsp;Damla Gökşen","doi":"10.1297/cpe.2021-0050","DOIUrl":"https://doi.org/10.1297/cpe.2021-0050","url":null,"abstract":"<p><p>The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo-18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.</p>","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 1","pages":"33-37"},"PeriodicalIF":1.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/14/cpe-31-033.PMC8713063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39660862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Congenital hypogonadotropic hypogonadism complicated by neuroblastoma. 先天性促性腺功能减退症合并神经母细胞瘤。
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-01 Epub Date: 2022-03-30 DOI: 10.1297/cpe.2021-0070
Yukiko Ueta, Keiko Aso, Youichi Haga, Hiroyuki Takahashi, Mari Satoh

A 3-mo-old male infant was referred to our hospital with micropenis. Since his serum LH, FSH, and testosterone levels were low (< 0.3 mIU/mL, 0.08 mIU/mL, and < 0.03 ng/mL, respectively), Kallmann syndrome/normosmic hypogonadotropic hypogonadism was suspected. In the process of searching for complications of Kallmann syndrome/normosmic hypogonadotropic hypogonadism, a right adrenal gland tumor was incidentally discovered. The patient was diagnosed with stage 1 neuroblastoma. A homozygous p.P147L (c.C440T) mutation in the KISS1R gene was detected as a cause of the congenital hypogonadotropic hypogonadism. KISS1-KISS1R signaling, which is essential for GnRH secretion, exhibits anti-metastatic and/or anti-tumoral roles in numerous cancers. High KISS1 expression levels reportedly predict better survival outcomes than low KISS1 expression levels in neuroblastoma. Therefore, decreased KISS1-KISS1R signaling may have played a role in the neuroblastoma in this patient.

一名3岁男婴因小阴茎转诊至我院。由于患者血清LH、FSH和睾酮水平较低(分别< 0.3 mIU/mL、0.08 mIU/mL和< 0.03 ng/mL),怀疑为Kallmann综合征/正常促性腺功能低下。在寻找Kallmann综合征/正常促性腺功能减退症并发症的过程中,偶然发现右侧肾上腺肿瘤。患者被诊断为1期神经母细胞瘤。在KISS1R基因中检测到p.P147L (c.C440T)纯合子突变是导致先天性促性腺功能低下的原因。KISS1-KISS1R信号是GnRH分泌所必需的,在许多癌症中具有抗转移和/或抗肿瘤作用。据报道,在神经母细胞瘤中,高KISS1表达水平比低KISS1表达水平预测更好的生存结果。因此,KISS1-KISS1R信号的减少可能在该患者的神经母细胞瘤中发挥了作用。
{"title":"Congenital hypogonadotropic hypogonadism complicated by neuroblastoma.","authors":"Yukiko Ueta,&nbsp;Keiko Aso,&nbsp;Youichi Haga,&nbsp;Hiroyuki Takahashi,&nbsp;Mari Satoh","doi":"10.1297/cpe.2021-0070","DOIUrl":"https://doi.org/10.1297/cpe.2021-0070","url":null,"abstract":"<p><p>A 3-mo-old male infant was referred to our hospital with micropenis. Since his serum LH, FSH, and testosterone levels were low (< 0.3 mIU/mL, 0.08 mIU/mL, and < 0.03 ng/mL, respectively), Kallmann syndrome/normosmic hypogonadotropic hypogonadism was suspected. In the process of searching for complications of Kallmann syndrome/normosmic hypogonadotropic hypogonadism, a right adrenal gland tumor was incidentally discovered. The patient was diagnosed with stage 1 neuroblastoma. A homozygous p.P147L (c.C440T) mutation in the <i>KISS1R</i> gene was detected as a cause of the congenital hypogonadotropic hypogonadism. KISS1-KISS1R signaling, which is essential for GnRH secretion, exhibits anti-metastatic and/or anti-tumoral roles in numerous cancers. High <i>KISS1</i> expression levels reportedly predict better survival outcomes than low <i>KISS1</i> expression levels in neuroblastoma. Therefore, decreased KISS1-KISS1R signaling may have played a role in the neuroblastoma in this patient.</p>","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 3","pages":"159-162"},"PeriodicalIF":1.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/2e/cpe-31-159.PMC9297168.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40694815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Markedly elevated troponin and NT-proBNP and myocardial dysfunction in an adolescent with severe diabetic ketoacidosis: A case report. 肌钙蛋白和NT-proBNP显著升高与严重糖尿病酮症酸中毒的青少年心肌功能障碍1例报告。
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-01 Epub Date: 2022-05-16 DOI: 10.1297/cpe.2022-0017
Irine-Ikbale Sakou, Alexandra Soldatou, Aristeidis Seretis, Evangelos Karanasios, George Paltoglou, Kyriaki Karavanaki

Severe diabetic ketoacidosis (DKA), rarely, may be associated with elevated troponin and proBNP levels in adults with a history of diabetes. However, few cases have reported this association in children with severe and complicated DKA. We describe a case of severe DKA (pH: 6.89, HCO3: 6.5) in a 14-yr-old female adolescent in which the symptoms of DKA were presented days before the diagnosis. The patient was under the effect of acidosis (Kussmaul respiration) for 12 h before admission to our hospital, where she was admitted in a critical clinical condition. After successful treatment with DKA with intensive intravenous fluid and regular insulin, the patient presented with abnormal cardiac rhythm, disturbance of interventricular septum motility, a mild decrease in left ventricular systolic function, negative T waves in leads III and aVF, and a marked increase in troponin and brain natriuretic peptide (NT-proBNP) levels. All abnormal findings completely resolved within 8 days after the initiation of DKA treatment. The phenomenon in our case was transient, and the patient had a good long-term outcome. However, it represents a challenge for clinicians; therefore, emphasis should be given to cardiac monitoring during the course of severe and prolonged DKA in children and adolescents.

严重的糖尿病酮症酸中毒(DKA),很少,可能与肌钙蛋白和proBNP水平升高与糖尿病史的成年人有关。然而,在患有严重和复杂DKA的儿童中,很少有病例报道这种关联。我们描述了一个病例严重DKA (pH: 6.89, HCO3: 6.5)在14岁的女性青少年中,DKA的症状是在诊断前几天提出的。患者入院前因酸中毒(Kussmaul呼吸)作用12小时,临床情况危重。经DKA强化静脉输液和常规胰岛素治疗成功后,患者出现心律异常,室间隔运动障碍,左室收缩功能轻度下降,导联III和aVF T波阴性,肌钙蛋白和脑钠肽(NT-proBNP)水平明显升高。所有异常表现在DKA治疗开始后8天内完全消失。在我们的病例中,这种现象是短暂的,患者有良好的长期预后。然而,这对临床医生来说是一个挑战;因此,在儿童和青少年严重和长期DKA过程中,应重视心脏监测。
{"title":"Markedly elevated troponin and NT-proBNP and myocardial dysfunction in an adolescent with severe diabetic ketoacidosis: A case report.","authors":"Irine-Ikbale Sakou,&nbsp;Alexandra Soldatou,&nbsp;Aristeidis Seretis,&nbsp;Evangelos Karanasios,&nbsp;George Paltoglou,&nbsp;Kyriaki Karavanaki","doi":"10.1297/cpe.2022-0017","DOIUrl":"https://doi.org/10.1297/cpe.2022-0017","url":null,"abstract":"<p><p>Severe diabetic ketoacidosis (DKA), rarely, may be associated with elevated troponin and proBNP levels in adults with a history of diabetes. However, few cases have reported this association in children with severe and complicated DKA. We describe a case of severe DKA (pH: 6.89, HCO3: 6.5) in a 14-yr-old female adolescent in which the symptoms of DKA were presented days before the diagnosis. The patient was under the effect of acidosis (Kussmaul respiration) for 12 h before admission to our hospital, where she was admitted in a critical clinical condition. After successful treatment with DKA with intensive intravenous fluid and regular insulin, the patient presented with abnormal cardiac rhythm, disturbance of interventricular septum motility, a mild decrease in left ventricular systolic function, negative T waves in leads III and aVF, and a marked increase in troponin and brain natriuretic peptide (NT-proBNP) levels. All abnormal findings completely resolved within 8 days after the initiation of DKA treatment. The phenomenon in our case was transient, and the patient had a good long-term outcome. However, it represents a challenge for clinicians; therefore, emphasis should be given to cardiac monitoring during the course of severe and prolonged DKA in children and adolescents.</p>","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 3","pages":"192-198"},"PeriodicalIF":1.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/34/cpe-31-192.PMC9297169.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40694818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Goiter in a 6-year-old patient with novel thyroglobulin gene variant (Gly145Glu) causing intracellular thyroglobulin transport disorder: Correlation between goiter size and the free T3 to free T4 ratio. 6岁新型甲状腺球蛋白基因变异(Gly145Glu)导致细胞内甲状腺球蛋白转运障碍患者的甲状腺肿:甲状腺肿大小与游离T3与游离T4比值的相关性
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-01 Epub Date: 2022-05-16 DOI: 10.1297/cpe.2022-0006
Misayo Matsuyama, Hirotake Sawada, Shinobu Inoue, Akira Hishinuma, Ryo Sekiya, Yuichiro Sato, Hiroshi Moritake

Thyroglobulin gene abnormalities cause thyroid dyshormonogenesis. A 6-yr-old boy of consanguineous parents presented with a large goiter and mild hypothyroidism (thyroid-stimulating hormone [TSH] 7.2 μIU/mL, free T3 [FT3] 3.4 pg/mL, free T4 [FT4] 0.6 ng/dL). Despite levothyroxine (LT4) administration and normal TSH levels, the goiter progressed slowly and increased rapidly in size at the onset of puberty. Thyroid scintigraphy revealed a remarkably high 123I uptake of 75.2%, with a serum thyroglobulin level of 13 ng/ml, which was disproportionately low for the goiter size. DNA sequencing revealed a novel homozygous missense variant, c.434G>A [p.Gly145Glu], in the thyroglobulin gene. Goiter growth was suppressed by increasing the LT4 dose. Thyroidectomy was performed at 17-yr-of-age. Thyroglobulin analysis of the thyroid tissue detected mutant thyroglobulin present in the endoplasmic reticulum, demonstrating that thyroglobulin transport from the endoplasmic reticulum to the Golgi apparatus was impaired by the Gly145Glu variant. During the clinical course, an elevated FT3/FT4 ratio was observed along with thyroid enlargement. A high FT3/FT4 ratio and goiter seemed to be compensatory responses to impaired hormone synthesis. Thyroglobulin defects with goiter should be treated with LT4, even if TSH levels are normal.

甲状腺球蛋白基因异常导致甲状腺激素生成障碍。6岁男童,近亲父母,甲状腺肿大,轻度甲状腺功能减退(促甲状腺激素[TSH] 7.2 μIU/mL,游离T3 [FT3] 3.4 pg/mL,游离T4 [FT4] 0.6 ng/dL)。尽管给予左旋甲状腺素(LT4)和正常的TSH水平,甲状腺肿进展缓慢,在青春期开始时迅速增大。甲状腺显像显示123I摄取量高达75.2%,血清甲状腺球蛋白水平为13 ng/ml,与甲状腺肿大不成比例地低。DNA序列分析发现了一种新的纯合子错义变异,c434g > a [p]。gly145 [glu],在甲状腺球蛋白基因中。增加LT4剂量可抑制甲状腺肿的生长。17岁时行甲状腺切除术。甲状腺组织的甲状腺球蛋白分析检测到内质网中存在突变的甲状腺球蛋白,表明Gly145Glu变异体损害了甲状腺球蛋白从内质网到高尔基体的运输。在临床过程中,FT3/FT4比值升高,甲状腺肿大。高FT3/FT4比率和甲状腺肿似乎是对激素合成受损的代偿反应。甲状腺球蛋白缺陷伴甲状腺肿应使用LT4治疗,即使TSH水平正常。
{"title":"Goiter in a 6-year-old patient with novel thyroglobulin gene variant (Gly145Glu) causing intracellular thyroglobulin transport disorder: Correlation between goiter size and the free T3 to free T4 ratio.","authors":"Misayo Matsuyama,&nbsp;Hirotake Sawada,&nbsp;Shinobu Inoue,&nbsp;Akira Hishinuma,&nbsp;Ryo Sekiya,&nbsp;Yuichiro Sato,&nbsp;Hiroshi Moritake","doi":"10.1297/cpe.2022-0006","DOIUrl":"https://doi.org/10.1297/cpe.2022-0006","url":null,"abstract":"<p><p>Thyroglobulin gene abnormalities cause thyroid dyshormonogenesis. A 6-yr-old boy of consanguineous parents presented with a large goiter and mild hypothyroidism (thyroid-stimulating hormone [TSH] 7.2 μIU/mL, free T3 [FT3] 3.4 pg/mL, free T4 [FT4] 0.6 ng/dL). Despite levothyroxine (LT4) administration and normal TSH levels, the goiter progressed slowly and increased rapidly in size at the onset of puberty. Thyroid scintigraphy revealed a remarkably high <sup>123</sup>I uptake of 75.2%, with a serum thyroglobulin level of 13 ng/ml, which was disproportionately low for the goiter size. DNA sequencing revealed a novel homozygous missense variant, c.434G>A [p.Gly145Glu], in the thyroglobulin gene. Goiter growth was suppressed by increasing the LT4 dose. Thyroidectomy was performed at 17-yr-of-age. Thyroglobulin analysis of the thyroid tissue detected mutant thyroglobulin present in the endoplasmic reticulum, demonstrating that thyroglobulin transport from the endoplasmic reticulum to the Golgi apparatus was impaired by the Gly145Glu variant. During the clinical course, an elevated FT3/FT4 ratio was observed along with thyroid enlargement. A high FT3/FT4 ratio and goiter seemed to be compensatory responses to impaired hormone synthesis. Thyroglobulin defects with goiter should be treated with LT4, even if TSH levels are normal.</p>","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 3","pages":"185-191"},"PeriodicalIF":1.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1d/21/cpe-31-185.PMC9297170.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40583170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The clinical course of Rathke's cleft cysts in pediatric patients: impact on growth and pubertal development. 儿童Rathke氏裂囊肿的临床过程:对生长和青春期发育的影响。
IF 1.4 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-01-01 Epub Date: 2021-11-01 DOI: 10.1297/cpe.2021-0034
Yousuke Higuchi, Kosei Hasegawa, Toshihide Kubo, Hiroyuki Tanaka, Hirokazu Tsukahara

Rathke's cleft cysts (RCCs) are non-neoplastic epithelial lesions in the sellar or suprasellar regions. RCCs are usually asymptomatic; however, some patients experience headaches, visual disturbances, and endocrine disorders. The best treatment for associated endocrinopathy remains elusive. We aimed to investigate the clinical course, magnetic resonance imaging findings, and response to therapy in 10 pediatric patients with RCCs and endocrinopathy. Growth impairment and precocious puberty were observed to be prevalent. One patient with suprasellar extension of RCC underwent surgery, while the others were treated medically. Of the nine patients, seven patients showed stable cyst size, while two patients displayed reduction in cyst size. Hormone replacement and gonadotropin suppression therapy were found to be effective. Imaging and endocrine follow-ups are warranted because of the potential for changes in the cyst size and hormonal changes.

Rathke's cleft囊肿(RCCs)是鞍区或鞍上区域的非肿瘤性上皮病变。rcc通常无症状;然而,一些患者会出现头痛、视觉障碍和内分泌紊乱。治疗相关内分泌疾病的最佳方法仍然难以捉摸。我们的目的是研究10例患有rcc和内分泌病变的儿童患者的临床病程、磁共振成像结果和对治疗的反应。生长障碍和性早熟普遍存在。一名患有肾细胞癌鞍上延伸的患者接受了手术,而其他患者则接受了药物治疗。9例患者中,7例囊肿大小稳定,2例囊肿大小减小。激素替代和促性腺激素抑制治疗是有效的。由于囊肿大小和激素变化的潜在变化,影像学和内分泌随访是必要的。
{"title":"The clinical course of Rathke's cleft cysts in pediatric patients: impact on growth and pubertal development.","authors":"Yousuke Higuchi,&nbsp;Kosei Hasegawa,&nbsp;Toshihide Kubo,&nbsp;Hiroyuki Tanaka,&nbsp;Hirokazu Tsukahara","doi":"10.1297/cpe.2021-0034","DOIUrl":"https://doi.org/10.1297/cpe.2021-0034","url":null,"abstract":"<p><p>Rathke's cleft cysts (RCCs) are non-neoplastic epithelial lesions in the sellar or suprasellar regions. RCCs are usually asymptomatic; however, some patients experience headaches, visual disturbances, and endocrine disorders. The best treatment for associated endocrinopathy remains elusive. We aimed to investigate the clinical course, magnetic resonance imaging findings, and response to therapy in 10 pediatric patients with RCCs and endocrinopathy. Growth impairment and precocious puberty were observed to be prevalent. One patient with suprasellar extension of RCC underwent surgery, while the others were treated medically. Of the nine patients, seven patients showed stable cyst size, while two patients displayed reduction in cyst size. Hormone replacement and gonadotropin suppression therapy were found to be effective. Imaging and endocrine follow-ups are warranted because of the potential for changes in the cyst size and hormonal changes.</p>","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"31 1","pages":"38-43"},"PeriodicalIF":1.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/1d/cpe-31-038.PMC8713062.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39660863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Clinical Pediatric Endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1